ACTIVE_NOT_RECRUITING

Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream Infections

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Streptococcus pneumoniae is a gram-positive (GP) bacteria responsible for common infections such as community-acquired pneumonia (CAP), as well as complicated infections such as bacteremia, infective endocarditis and meningitis. S. pneumoniae bacteremia ranks among the top 10 most common pathogens associated with bloodstream infections and correlates with high morbidity and mortality worldwide.

Official Title

Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream

Quick Facts

Study Start:2023-06-23
Study Completion:2026-06-23
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT06096025

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 75 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Not specified
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * • ≥18 years of age
  2. * S. pneumoniae isolated from ≥1 blood cultures
  3. * Active IV antibiotic therapy within 48 hours of the first positive blood culture(7,8)
  4. * Clinical stability by day 10 of therapy
  1. * • Treatment duration \<5 days or \>16 days
  2. * Death before completion of therapy (\<10 days vs. ≥ 10 days )
  3. * Polymicrobial BSI
  4. * Invasive infection caused by S. pneumoniae (endocarditis, meningitis, and lung abscess)

Contacts and Locations

Principal Investigator

Matthew Crotty, PharmD
PRINCIPAL_INVESTIGATOR
Methodist Midlothian Medical Center

Study Locations (Sites)

Methodist Dallas Medical Center
Dallas, Texas, 75203
United States

Collaborators and Investigators

Sponsor: Methodist Health System

  • Matthew Crotty, PharmD, PRINCIPAL_INVESTIGATOR, Methodist Midlothian Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-06-23
Study Completion Date2026-06-23

Study Record Updates

Study Start Date2023-06-23
Study Completion Date2026-06-23

Terms related to this study

Additional Relevant MeSH Terms

  • Streptococcus Pneumoniae